Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$0.22
$0.14
$0.15
$7.10
$995K1.1286,634 shsN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$3.20
-0.6%
$5.29
$2.75
$15.15
$4.01M0.7154,362 shs27,971 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.59
-1.5%
$6.41
$2.98
$80.10
$3.73M2.78500,912 shs9,168 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$2.17
-0.9%
$2.11
$1.73
$7.05
$3.91M0.7312,542 shs4,964 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00%0.00%0.00%0.00%+50.79%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
0.00%-14.21%-33.05%-46.71%-69.56%
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00%-4.91%+22.95%+36.72%-85.75%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.00%+1.88%+2.84%-16.22%-51.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$0.22
$0.14
$0.15
$7.10
$995K1.1286,634 shsN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$3.20
-0.6%
$5.29
$2.75
$15.15
$4.01M0.7154,362 shs27,971 shs
SciSparc Ltd. stock logo
SPRC
SciSparc
$6.59
-1.5%
$6.41
$2.98
$80.10
$3.73M2.78500,912 shs9,168 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$2.17
-0.9%
$2.11
$1.73
$7.05
$3.91M0.7312,542 shs4,964 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00%0.00%0.00%0.00%+50.79%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
0.00%-14.21%-33.05%-46.71%-69.56%
SciSparc Ltd. stock logo
SPRC
SciSparc
0.00%-4.91%+22.95%+36.72%-85.75%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.00%+1.88%+2.84%-16.22%-51.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00
N/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
1.00
SellN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BIOR, XRTX, SILO, and SPRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
UpgradeSell (E+)Sell (D-)
6/24/2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
Reiterated RatingSell (E+)
6/11/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
DowngradeSell (D-)Sell (E+)
5/27/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
UpgradeSell (E+)Sell (D-)
5/26/2026
SciSparc Ltd. stock logo
SPRC
SciSparc
Reiterated RatingSell (E+)
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$892K1.12N/AN/A($36.43) per share-0.01
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$72.10K55.61N/AN/A$7.10 per share0.45
SciSparc Ltd. stock logo
SPRC
SciSparc
$856K4.36N/AN/A$12.93 per share0.51
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/A$1.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$4.36N/AN/AN/A-6,726.39%-78.94%-63.86%9/2/2026 (Estimated)
SciSparc Ltd. stock logo
SPRC
SciSparc
-$12.18MN/AN/AN/AN/AN/AN/AN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-$2.66M-$2.63N/AN/AN/AN/A-150.01%-106.53%8/17/2026 (Estimated)

Latest BIOR, XRTX, SILO, and SPRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32N/AN/AN/A$0.02 millionN/A
8/15/2026Q2 2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A-$1.05N/A-$1.05N/AN/A
8/13/2026Q2 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32-$0.76-$0.44-$0.76$0.02 millionN/A
5/16/2026Q1 2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A-$0.58N/A-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
SciSparc Ltd. stock logo
SPRC
SciSparc
N/AN/AN/AN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/A
0.05
0.05
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
9.65
9.65
SciSparc Ltd. stock logo
SPRC
SciSparc
N/A
2.41
2.38
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A
0.86
0.86

Institutional Ownership

CompanyInstitutional Ownership
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
43.74%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%
SciSparc Ltd. stock logo
SPRC
SciSparc
25.06%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.23%

Insider Ownership

CompanyInsider Ownership
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
51.08%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
SciSparc Ltd. stock logo
SPRC
SciSparc
1.52%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
1204.52 million2.21 millionNo Data
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
21.25 million1.21 millionNot Optionable
SciSparc Ltd. stock logo
SPRC
SciSparc
4566,000557,000Not Optionable
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A1.82 million1.69 millionNot Optionable

Recent News About These Companies

XORTX Therapeutics Inc.
XORTX Therapeutics Inc.: XORTX Announces Director Resignation
XORTX Announces Director Resignation
XORTX Announces Director Resignation
XORTX Appoints New Director
XORTX Appoints New Director
XORTX Announces Closing of US$5 Million Public Offering
XORTX Announces US$5 Million Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biora Therapeutics stock logo

Biora Therapeutics NASDAQ:BIOR

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$3.20 -0.02 (-0.62%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$3.20 -0.01 (-0.16%)
As of 08/14/2026 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

SciSparc stock logo

SciSparc NASDAQ:SPRC

$6.59 -0.10 (-1.49%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$6.60 +0.01 (+0.15%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

XORTX Therapeutics stock logo

XORTX Therapeutics NASDAQ:XRTX

$2.17 -0.02 (-0.91%)
Closing price 08/14/2026 03:47 PM Eastern
Extended Trading
$2.15 -0.02 (-0.74%)
As of 08/14/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.